Medigen Vaccine Biologics Capital Reinvestment Ratio

Latest as of December 2025: 0.03x

Medigen Vaccine Biologics capital reinvestment ratio. Medigen Vaccine Biologics (6547) has a Capital Reinvestment Ratio of 0.03x as of December 2025, meaning it reinvests 0% of its operating cash flow (NT$101.08 Million) in capital expenditures (NT$3.54 Million). Check 6547 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

0.03x
Capex / Operating Cash Flow

Operating Cash Flow

NT$101.08 Million
TWD

Capital Expenditures

NT$3.54 Million
TWD

Data as of

Dec 2025
Most recent filing

Capital Reinvestment Ratio of Medigen Vaccine Biologics (2015–2024)

Capital reinvestment ratio of Medigen Vaccine Biologics from 2015 to 2024. This chart tracks Medigen Vaccine Biologics's Capital Reinvestment Ratio across 3 annual periods. Also explore 6547 net asset momentum to track the company's year-over-year net asset growth rate.

Medigen Vaccine Biologics Capital Reinvestment Ratio by Year (2015–2024)

Medigen Vaccine Biologics capital reinvestment ratio by year from 2015 to 2024. For the full cash flow conversion analysis, see how efficiently does Medigen Vaccine Biologics generate cash.

Year Reinvestment Ratio Operating CF (TWD) Capital Expenditures YoY Change
2024 0.86x NT$40.75 Million NT$34.98 Million ▲ +268.8%
2021 0.23x NT$579.89 Million NT$134.97 Million ▼ -89.0%
2015 2.11x NT$216.26 Million NT$457.15 Million —
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow